Kevin McCulloch, an officer at Xeris Biopharma Holdings, Inc., has filed to sell 25,000 shares of the company's common stock. This filing, made on November 5, 2026, indicates a significant move by the executive as part of a pre-arranged trading plan.

Xeris Biopharma Holdings, Inc. is classified under the pharmaceutical preparations sector, specifically identified by the SIC code 2834. The company is publicly traded on NASDAQ and has been active in the pharmaceutical industry, focusing on innovative treatments.

According to the filing, McCulloch's sale of shares is part of a structured plan, as he has previously sold shares under a 10b5-1 plan. The filing notes that McCulloch acquired these shares through restricted stock units that vested between January 31, 2024, and January 31, 2025. The total market value of the shares to be sold is approximately $261,500.

This action may impact various stakeholders, including investors and analysts who monitor executive trading activities. The sale could signal McCulloch's confidence in the company's future while also raising questions about insider trading practices within the pharmaceutical sector.

Details were not available in the SEC filing regarding any subsequent actions following this sale. However, McCulloch's ongoing sales under the 10b5-1 plan suggest a strategic approach to managing his holdings in Xeris Biopharma.